Kava

Metadata

Approved Indications

Commission E (Germany, pre-ban)

• Approved (1990): Conditions of nervous anxiety, stress, and restlessness
• Withdrawn (2002): Marketing authorizations revoked due to hepatotoxicity concerns
• Court reversal (2014): German Upper Administrative Court ruled the ban was not justified
• Reimposed (2019): BfArM issued a renewed ban, which remains controversial

ESCOP

• Approved: Anxiety, tension, and restlessness of non-psychotic origin

EMA/HMPC

• Assessment completed but no positive monograph issued due to safety concerns
• The HMPC report has been criticized by researchers as requiring “major revision” for inconsistencies in safety analysis

Agreement/Disagreement

There is a notable split: the scientific/clinical community (as reflected in Cochrane reviews, meta-analyses, and published expert opinions) broadly supports kava’s efficacy and argues the safety concerns are manageable through quality control. European regulatory bodies (particularly BfArM and EMA) have maintained a cautious/negative stance. This regulatory-scientific disconnect is one of the most significant controversies in European phytotherapy.

Conditions Treated

Primary (Strong Evidence)

• Non-psychotic anxiety disorders — Including generalized anxiety disorder (GAD), tension, and nervous restlessness
• Stress-related anxiety — Both chronic and situational

Secondary (Moderate Evidence)

• Insomnia associated with anxiety — Kavalactones have some sedative properties at higher doses
• Menopausal anxiety — Some clinical evidence

Traditional Use (Pacific Islands)

• Ceremonial and social use throughout Polynesia, Melanesia, and Micronesia for millennia
• Traditional preparation: aqueous extract of root/rhizome in water or coconut milk
• The “Pacific kava paradox”: extensive traditional use in Pacific populations without endemic liver disease, contrasting with the European hepatotoxicity cases

Mechanism of Action

Primary Mechanisms

1. GABA-A receptor potentiation: Kavalactones enhance GABAergic neurotransmission primarily through potentiation of GABA-A receptors via alteration of lipid membrane structure (rather than direct receptor binding like benzodiazepines). Kavain and dihydrokavain have the most significant anxiolytic activity.
2. Voltage-gated sodium channel modulation: Kavain and dihydromethysticin block voltage-gated sodium channels, which may contribute to both anxiolytic and muscle-relaxant effects.
3. Monoamine reuptake inhibition: Kavalactones inhibit reuptake of noradrenaline and dopamine, particularly in the prefrontal cortex.

Secondary Mechanisms

4. MAO-B inhibition: Reversible inhibition of monoamine oxidase B (desmethoxyyangonin is most active)
5. Glutamate inhibition: Some kavalactones reduce excitatory glutamatergic neurotransmission
6. Cannabinoid receptor interaction: Yangonin has affinity for CB1 receptors [NEEDS-RESEARCH — significance unclear]

Key Pharmacological Advantage

Unlike benzodiazepines, kava provides anxiolysis without significant sedation, cognitive impairment, or loss of mental acuity at therapeutic doses. This is a clinically meaningful distinction.

Clinical Evidence Summary

Cochrane Review (Pittler and Ernst)

• 12 double-blind RCTs, n = 700
• Conclusion: Kava extract is a safe and effective symptomatic treatment for anxiety
• Used primarily the Hamilton Anxiety Rating Scale (HAMA) as the outcome measure

WS 1490 Meta-Analysis (Witte et al., 2005)

• Six placebo-controlled RCTs with WS 1490 specifically
• Odds ratio for treatment success: 3.3 (95% CI 2.09-5.22)
• Doses ranged from 150-300 mg/day
• Trial duration: 4-24 weeks

Key Individual Trials

Comparison with Benzodiazepines

• The Malsch & Keiser (2001) trial is particularly notable: kava was used to facilitate benzodiazepine tapering, suggesting it may serve as a transition agent
• No head-to-head superiority trials vs. benzodiazepines, but effect sizes suggest comparable efficacy for mild-moderate anxiety

The Hepatotoxicity Controversy

This is one of the most important regulatory stories in modern phytotherapy and merits detailed treatment.

Timeline

1. Pre-1998: Kava extracts widely marketed in Europe, especially Germany. Millions of daily doses sold without liver safety signals.
2. 1999-2001: First case reports of hepatotoxicity emerge in Germany and Switzerland. Approximately 100 cases worldwide eventually reported, including 11 cases of liver failure requiring transplantation, and 3-4 deaths.
3. 2002: German BfArM withdraws marketing authorization for kava-containing products. Other EU countries follow. Effective ban across Europe.
4. 2002-2013: Intense scientific debate. Multiple reviews question the causality assessment of the case reports.
5. 2014: German Upper Administrative Court overturns the ban, ruling that BfArM had not sufficiently proven the safety risk and stating “pure speculation is not probable cause.”
6. 2019: BfArM reimposed the ban, sparking renewed controversy.

Critical Analysis of the Hepatotoxicity Cases

Quality Control Issues (The Dominant Hypothesis)

The strongest scientific argument is that the hepatotoxicity was not caused by kava per se, but by specific quality problems:

1. Tudei (two-day) kava vs. noble kava: The first hepatotoxicity cases correlated temporally with the introduction of “tudei kava” (Piper wichmannii and certain P. methysticum cultivars) into the supply chain, replacing the “noble kava” varieties used traditionally and in earlier clinical trials. Tudei kava has a different kavalactone profile and contains higher levels of potentially hepatotoxic flavokavains.

2. Acetone vs. ethanol/water extraction: Traditional Pacific preparation uses water or coconut milk. European medicinal products used ethanol or (later) acetone extraction. Acetone extraction may extract hepatotoxic compounds not present in aqueous or ethanolic preparations.

3. Use of non-root plant parts: Some manufacturers reportedly used leaves and stem peelings (which contain hepatotoxic pipermethystine alkaloids) to increase yield, rather than restricting to the traditional root/rhizome.

4. Pre-existing liver damage or comedication: Many case reports involved patients with pre-existing liver conditions or concurrent hepatotoxic medications.

Immunoallergic/Idiosyncratic Hypothesis

• The pattern of liver injury (rapid onset in some cases, positive rechallenge in rare cases) suggests an idiosyncratic or immunoallergic mechanism in susceptible individuals
• CYP2D6 poor metabolizer status has been hypothesized as a risk factor
• Estimated incidence: approximately 1 in 60,000-125,000 [UNCERTAIN — estimates vary widely]

The Pacific Kava Paradox

• Pacific Island populations have consumed aqueous kava preparations for centuries to millennia without endemic liver disease
• Epidemiological studies in Tonga, Fiji, and Vanuatu show no elevated rates of liver disease attributable to kava
• This paradox is most parsimoniously explained by the differences in preparation (aqueous extraction of noble kava root only)

European vs. US/Anglophone Consensus

Safety Profile

Contraindications

• Pre-existing liver disease or hepatic insufficiency
• History of hepatotoxicity from any cause
• Concurrent use of hepatotoxic drugs (including alcohol)
• Known hypersensitivity
• EMA/HMPC: Effectively contraindicated by market withdrawal in much of EU

Drug Interactions

• CYP450 inhibition: Kava inhibits CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4, and CYP4A9/11 in vitro. Clinical significance is uncertain for most, but caution is warranted with drugs metabolized by these enzymes.
• Additive sedation: With benzodiazepines, barbiturates, alcohol, and other CNS depressants
• Levodopa: Case report of reduced efficacy (possible dopaminergic interaction)
• Hepatotoxic drugs: Additive liver injury risk

Side Effects (at recommended doses, quality product)

• Common: Mild GI discomfort
• Occasional: Headache, dizziness
• Kava dermopathy: Chronic high-dose use can cause a reversible, scaly, yellowish skin condition (pellagra-like rash)
• Heavy chronic use: Elevated GGT, possible hepatic effects
• Overall: In controlled clinical trials with WS 1490, adverse event rates were comparable to placebo

Pregnancy and Lactation

• Pregnancy: Contraindicated. Kavalactones cross the placenta. No human safety data. Animal studies insufficient.
• Lactation: Contraindicated. Kavalactones are excreted in breast milk. Traditional Pacific practice advises against kava during lactation.

Hepatic Monitoring

If kava is used therapeutically (in jurisdictions where available):

• Baseline liver function tests (LFTs) before starting
• Repeat LFTs at 4-8 weeks
• Discontinue immediately if symptoms of hepatotoxicity emerge (jaundice, dark urine, unusual fatigue, right upper quadrant pain)
• Limit duration to 3 months without physician supervision

Clinical Dosage

Standard Anxiolytic Dose

• Kavalactones: 120-280 mg/day
• WS 1490 extract: 100-300 mg/day (standardized to 70% kavalactones, providing 70-210 mg kavalactones)
• Most clinical trials used doses in the range of 150-300 mg/day of WS 1490
• Duration in trials: 4-24 weeks

Commission E (Pre-ban)

• Preparations equivalent to 60-120 mg kavalactones per day
• Duration: not to exceed 3 months without medical advice

Traditional Pacific Dose

• Aqueous root extract; highly variable but typically 750 mL-1 L of prepared kava beverage containing variable kavalactone concentrations

Sources

• Cochrane Review: Pittler MH, Ernst E. Kava extract for treating anxiety. Cochrane Database Syst Rev. 2003
• Witte S et al. Meta-analysis of the efficacy of the acetonic kava-kava extract WS 1490 in patients with non-psychotic anxiety disorders. Phytother Res. 2005;19(3):183-188
• Sarris J et al. Kava: A Comprehensive Review of Efficacy, Safety, and Psychopharmacology. Aust N Z J Psychiatry. 2011;45(1):27-35
• Teschke R et al. Kava hepatotoxicity in traditional and modern use. Ann Hepatol. 2012. PMC3269575
• German Kava Ban Lifted by Court (Teschke R, 2015). PubMed 26695707
• LiverTox: Kava Kava (NCBI NBK548637)
• CDC MMWR. Hepatic Toxicity Possibly Associated with Kava-Containing Products. 2002;51(47):1065-1067
• Schmidt M. Health policy versus kava (Piper methysticum). J Ethnopharmacol. 2021;263. PubMed 33189846
• Ernst E. A re-evaluation of kava. Br J Clin Pharmacol. 2007. PMC2048557
• Ooi SL et al. Kava for Generalized Anxiety Disorder: A Review of Current Evidence. J Altern Complement Med. 2018

Connections

• Compare with other anxiolytics: Lavender (Silexan — no hepatotoxicity concerns), Passionflower
• GABA mechanism shared with: Valerian, Hops, Passionflower